Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CLDX
#3995
Celldex Therapeutics, Inc
30.090
0
+0.40%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+0.40%
Mudança mensal
+14.80%
Mudança em 6 meses
+10.46%
Mudança anual
+10.46%
Fechamento anterior
29.970
0
Open
30.000
0
Bid
Ask
Low
30.000
0
High
30.090
0
Volume
102
Mercados
Ações
Cuidados de saúde
CLDX
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
39.61 M
46.74 M
47.21 M
55.9 M
66.38 M
66.57 M
—
Valuation ratios
Enterprise value
650.21 M
1.77 B
2.02 B
2.22 B
1.65 B
1.78 B
5.98 B
Price to earnings ratio
—
-23.56
-18.08
-13.84
-10.31
-6.96
-28.1
Price to sales ratio
—
0.36
0.86
0.28
0.23
1.17
2.21
Price to cash flow ratio
—
0.03
0.02
0.02
0.01
0.01
0.03
Price to book ratio
—
0
0.01
0
0
0
0
Enterprise value to EBITDA ratio
-30.59
-108.09
-91.6
-104.31
-57.79
-45.5
—
Profitability ratios
Return on assets %
0.25
0.16
0.24
0.2
0.13
0.44
0.41
Return on equity %
0.29
0.17
0.26
0.21
0.14
0.49
0.44
Return on invested capital %
483.12
711.84
937.82
1 040.56
1 165.13
2 329.78
—
Gross margin %
97.3
97.85
95.76
95.64
97.15
87.06
400
Operating margin %
854.06
1 531.78
4 889.01
2 245.27
2 778.89
18.6 K
-7.27 M
EBITDA margin %
-286.52
-351.43
-935.09
-309.79
-406.48
-2 530.81
—
Net margin %
805.88
1 516.04
3 616.25
1 331.85
1 462.49
16.75 K
-6.62 M
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
13.93
24.86
17.07
13.87
18.91
10.49
64.83
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.01
0.01
0.02
0.01
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
1 420.57
2 211.65
2 214.7
2 450.5
3 175.83
3 176.63
EBIT per share
—
-452.83
-531.82
-502.2
-492.46
-639.56
—
EBITDA per share
—
-381.27
-470.06
-440.11
-443.12
-588.68
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
9 522.98
6 503.84
8 743.17
11.26 K
7 807.25
36.22 K
Net current asset value per share
—
9 583.37
6 775.57
8 910.26
11.6 K
8 049.5
37.37 K
Tangible book value per share
—
9 150.59
6 377.2
8 296.99
11.18 K
7 527.25
35.77 K
Working capital per share
—
9 197.83
6 378.67
8 267.83
10.99 K
7 281.82
34.92 K
Book value per share
—
9 784.84
6 957.09
8 858.2
11.6 K
7 936.6
37.41 K
Notícias
Celldex apresenta dados de fase 2 para tratamento de urticária crônica
Celldex presents phase 2 data for chronic urticaria treatment
Celldex Therapeutics Stock Earns 88 RS Rating
Lucro da Celldex Therapeutics veio abaixo das projeções por $0,21; receita menor do que estimativas
Celldex Therapeutics earnings missed by $0.21, revenue fell short of estimates
Ações da Celldex Therapeutics atingem máxima de 52 semanas a US$ 30,66
Celldex Therapeutics stock hits 52-week high at 30.66 USD
Stifel reitera classificação das ações da Celldex Therapeutics com base no progresso do estudo
Stifel reiterates Celldex Therapeutics stock rating on trial progress
Celldex conclui recrutamento da Fase 3 antes do previsto
Celldex completes Phase 3 enrollment for CSU treatment ahead of schedule
Cantor Fitzgerald reitera classificação acima da média para ações da Celldex